These findings, along with the activity and safety results of ELIANA, suggest a favourable benefit–risk profile of tisagenlecleucel in the treatment of paediatric and young adult patients with relapsed or refractory B-cell acute lymphoblastic leukaemia.
Despite affecting one in every two people in their lifetime, cancer is no longer always terminal. Scientific advances and their implementation in clinical practice are…
Last week, the European Commission approved a €2 billion plan by the Dutch government, known as the PALLAS project, to build a high-performance research reactor…
The UK government is contemplating banning smoking in selected outdoor public places, according to official papers leaked to a British newspaper. The proposals would prohibit…
A 53-year-old male patient presented to Mayo Clinic in Rochester (MN, USA) in February, 2022, with chest pain. He had an abnormal stress echocardiogram, prompting…
Imatinib interruption in patients with GIST without progressive disease is not recommended. Imatinib interruption in non-progressing patients with GIST was associated with rapid progression, faster…
A thoracic radiotherapy boost, based on interim [18F]FDG-PET, led to a meaningful local control rate with no difference in adverse events between the two groups…
The Lancet Oncology is delighted to announce that we will be entering a collaboration with the European Society for Radiotherapy and Oncology (ESTRO) and their…
A new analysis by the US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) has revealed that improvements in routine coverage of the…
A UK patient with lung cancer became the first to receive a groundbreaking new vaccine against the disease at the University College London Hospitals NHS…
